Evidence map›Paper›PMID 34680966›Full record

ReviewGenes2021

Naoki Yamamoto, Nao Nishida, Rain Yamamoto, Takashi Gojobori, Kunitada Shimotohno, Masashi Mizokami, Yasuo Ariumi

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. TheInternational journal of molecular sciences · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Naoki YamamotoGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
Nao NishidaGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
Rain YamamotoIntelligence for Medical and Nutritional Research, Tokyo 145-0065, Japan.
Takashi GojoboriComputational Bioscience Research Center, Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal 23955, Saudi Arabia.
Kunitada ShimotohnoGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
Masashi MizokamiGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
Yasuo AriumiDivision of Retroelement, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.ORCID 0000-0002-3109-9678
National Center for Global Health and Medicine · JPKing Abdullah University of Science and Technology · SAKumamoto University · JP

Funding

Japan Agency for Medical Research and Development JP19fk0108104
6 · The paper itself

Abstract

The renin-angiotensin-aldosterone system (RAAS) appears to play an important role in SARS-CoV-2 infection. Polymorphisms within the genes that control this enzymatic system are candidates for elucidating the pathogenesis of COVID-19, since COVID-19 is not only a pulmonary disease but also affects many organs and systems throughout the body in multiple ways. Most striking is the fact that ACE2, one of the major components of the RAAS, is a prerequisite for SARS-COV-2 infection. Recently, we and other groups reported an association between a polymorphism of the

Indexed as

COVID-19Gene Expression Regulation, ViralGenotypeINDEL MutationPeptidyl-Dipeptidase APolymorphism, GeneticHumansRisk FactorsSARS-CoV-2ACE protein, humanPeptidyl-Dipeptidase AACE1 I/D polymorphismAlucomorbiditiesCOVID-19 symptomsRAASSARS-CoV-2

Identifiers

PMID34680966
PMCPMC8535484
OpenAlexW3204523039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.